Guard Medical Reports Enrollment of the first 5 Patients in the Post-market Study of its NPseal™

“The first cases demonstrate fast application and easy activation of the NPsealTM” stated Machiel van der Leest, CEO of Guard Medical. “This ease of use combined with its cost effectiveness makes prophylactic use of NPWT for closed surgical wounds possible.” 

Continue ReadingGuard Medical Reports Enrollment of the first 5 Patients in the Post-market Study of its NPseal™